Sun Pharma shares slip 3% after BofA downgrade on premium valuations

Bank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya’s Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.

from Economic Times https://ift.tt/ibjxko3